로딩 중…
지수 로딩 중…
BioNote, Inc.
377740· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩4,520-1.09%
2026-08-04
Financials
Valuation Metrics
BioNote, Inc.'s Market Cap is ₩4605B. At end of 2025 it was ₩5573B. Ranked #475 of 2,436 in KR market (top 19%), #301 of 787 on KOSPI (top 38%), #55 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 24%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 460.52B KRW | KR#475/2,436 Sec#55/234 |
| Revenue | 122.44B KRW | KR#1,284/2,436 Sec#81/234 |
| Net Income | -50.23B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 1.61T KRW | KR#341/2,436 Sec#15/234 |
| Net Assets | 1.54T KRW | KR#210/2,436 Sec#8/234 |
| Employees | 313 | KR#762/2,436 Sec#67/234 |
| Value | ||
| P/B | 0.30x | KR#328/2,436 Sec#11/234 |
| P/S | 3.76x | KR#2,071/2,436 Sec#134/234 |
| EV/EBITDA | 22.09x | KR#1,064/2,436 Sec#63/234 |
| FCF Yield | 1.36% | KR#1,118/2,436 Sec#78/234 |
| Profitability | ||
| ROE | -3.26% | KR#1,678/2,436 Sec#121/234 |
| ROA | -3.12% | KR#1,773/2,436 Sec#130/234 |
| Op. Margin | 14.99% | KR#280/2,436 Sec#24/234 |
| Revenue Growth | 14.49% | KR#768/2,436 Sec#68/234 |
| Earnings Growth | 925.36% | KR#65/2,436 Sec#4/234 |
| Financial Health | ||
| Debt Ratio | 104.40% | KR#352/2,436 Sec#47/234 |
| Total Debt | 0 KRW | KR—/2,436 Sec—/234 |
| FCF | 6.27B KRW | KR#843/2,436 Sec#57/234 |
| Cash | 55.08B KRW | KR#702/2,436 Sec#40/234 |
| Current Ratio | 10.15x | KR#100/2,436 Sec#26/234 |
| Net Debt/EBITDA | -3.00x | KR#202/2,436 Sec#7/234 |
| Dividend | ||
| Div. Yield | 4.99% | KR#274/2,436 Sec#9/234 |
| Div. Growth | 14.00% | KR#518/2,436 Sec#28/234 |
| Performance | ||
| 1Y Return | -12.91% | KR#1,054/2,436 Sec#79/234 |
| 1M Return | -3.62% | KR#1,267/2,436 Sec#127/234 |
| From 52W High | -28.48% | KR#363/2,436 Sec#23/234 |
| 1Y MDD | -29.94% | KR#209/2,436 Sec#13/234 |
| Trading | ||
| Volume | 71,703 shares | KR#1,132/2,436 Sec#109/234 |
| Foreign Own. | 0.48% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -492 KRW | KR—/2,436 Sec—/234 |
| BPS | 15,288 KRW | KR#643/2,436 Sec#41/234 |
Company Info
Bionote, established in 2003 and listed on the KOSPI market in 2022, specializes in animal diagnostic products and bio-content. Utilizing its unique recombinant antigen and antibody manufacturing technology, it produces and distributes diverse diagnostic products and bio-content across over 80 countries. The company is expanding its business into molecular and biochemical diagnostics. It aims to increase global market share by launching fully automated point-of-care diagnostic devices.